세계의 디지털 병리 검사 시장 : 제품별, 유형별, 용도별, 최종 사용자별, 지역별 예측(-2030년)

The market for digital pathology is segmented into three categories based on type: scanners, storage systems, and software. Given the significance of these devices in the digital pathology workflow, the scanners segment accounted for the largest share of the product category in 2024. Scanners are critical in enabling pathologists to view and analyze tissue samples on computer screens, as scanners convert physical glass slides to high-resolution digital images. The development of diagnostic remote access is paramount for improved accessibility and efficiency of pathology services by allowing pathologists to evaluate cases from any physical location, hence, the demand for scanners. The advancements in scanner technology, such as improved scanning rates and greater resolution imaging, have led to increased workflow, improved diagnostic accuracy, and value for investment for laboratories or medical facilities.

By type, the human pathology segment is expected to hold the largest share during the forecast period.

The human pathology segment is expected to occupy the largest share of the digital pathology market throughout the forecast period largely due to the rising global burden of complex and chronic diseases, including cancer, cardiovascular diseases, and infections, which demand timely and accurate diagnostic outcomes.

Digital pathology, examination, and diagnosis, typically performed under the eyepiece of a microscope, are advantageous in many aspects, such as producing high-resolution images, providing automated analytics, allowing for image storage, cloud storage, and telepathology slide-sharing services. Equally important is the unparalleled advantage of being able to provide remote consultation that may involve co-consultation and coordination at various sites and second opinions from specialists.

Furthermore, digital pathology is quickly being adopted and evolving to integrate the newest technologies such as artificial intelligence (AI), machine learning (ML), deep learning image recognition, which are all improving diagnostic accuracy, decreasing turnaround time, and even aiding in recognizing subtle histological patterns, which makes digital pathology a foundational element of practice in laboratories and hospitals around the world.

North America is expected to lead the global digital pathology market during the forecast period.

North America led the digital pathology market in 2024 due to a mature healthcare system and large financial investments toward developing healthcare technology. The regulatory environment in North America-especially in the US and Canada-supports a relatively faster review and approval process for emerging digital pathology technologies. This, combined with growing awareness among healthcare providers and rising demand for advanced diagnostic solutions, has driven strong adoption of digital pathology across the region.

Breakdown of supply-side primary interviews, by company type, designation, and region:

• By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
• By Designation: C-level (35%), Director-level (25%), and Others (40%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and Middle East & Africa (5%)

List of Companies Profiled in the Report

Danaher Corporation (US), Koninklijke Philips N.V. (Netherlands), Hamamatsu Photonics K.K. (Japan), F. Hoffmann-La Roche Ltd. (Switzerland), 3DHISTECH (Hungary), Apollo Enterprise Imaging (US), XIFIN, Inc. (US), Huron Digital Pathology (Canada), Hologic, Inc. (US), Corista (US), Indica Labs Inc. (US), Objective Pathology Services Limited (Canada), Sectra AB (Sweden), OptraSCAN (US), Akoya Biosciences, Inc. (US), Glencoe Software, Inc. (US), Aiforia (Finland), Paige AI, Inc. (US), Fujifilm Holdings Corporation (Japan), Proscia Inc. (US), KONFOONG BIOTECH INTERNATIONAL CO., LTD. (China), Mikroscan Technologies, Inc. (US), PathAI (US), Motic Digital Pathology (US), and Kanteron Systems (Spain)

Research Coverage

This report studies the digital pathology market based on product, type, application, end user, and region. The report also analyses factors (such as drivers, opportunities, and challenges) affecting market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total digital pathology market. The report forecasts the revenue of the market segments with respect to five major regions.

Reasons to Buy the Report

This report also includes.

• Analysis of key drivers (Growing adoption of AI-enabled digital pathology, rising burden of cancer, diabetes, and chronic diseases, expansion of digital pathology in drug discovery and biomarker validation, Cancer screening programs in emerging markets), restraints (High initial capital costs, Data interoperability issues with existing lab systems, regulatory and reimbursement uncertainty), opportunities (Affordable scanner development for low-resource settings, growing preference for personalized medicine, government-backed digitization in emerging economies) challenges (Shortage of skilled pathologists and technicians, algorithm validation issues, data security and patient privacy concerns), are contributing the growth of the digital pathology market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new software launches in the digital pathology market
• Market Development: Comprehensive information about lucrative markets and analysis of the authentication and brand protection market across varied regions
• Market Diversification: Exhaustive information about the software portfolios, growing geographies, recent developments, and investments in the digital pathology market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, company evaluation quadrant, and capabilities of leading players in the global digital pathology market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
  • 1.3.3 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 RESEARCH METHODOLOGY DESIGN
• 2.3 MARKET SIZE ESTIMATION
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 MARKET ASSUMPTIONS
  • 2.6.1 OVERALL STUDY ASSUMPTIONS
• 2.7 RISK ASSESSMENT
• 2.8 RESEARCH LIMITATIONS
  • 2.8.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.8.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 DIGITAL PATHOLOGY MARKET OVERVIEW
• 4.2 NORTH AMERICA: DIGITAL PATHOLOGY MARKET, BY END USER AND COUNTRY (2024)
• 4.3 DIGITAL PATHOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.4 DIGITAL PATHOLOGY MARKET: REGIONAL MIX

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 AI-enabled digital pathology improving lab throughput
    • 5.2.1.2 Rising burden of cancer, diabetes, and cardiovascular diseases
    • 5.2.1.3 Expansion of digital pathology in drug discovery and biomarker validation
    • 5.2.1.4 National cancer screening programs in emerging markets
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High initial capital cost of digital pathology systems
    • 5.2.2.2 Data interoperability issues with existing lab systems
    • 5.2.2.3 Regulatory and reimbursement uncertainty
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Affordable scanner development for low-resource settings
    • 5.2.3.2 Personalized medicine driving precision diagnostics
    • 5.2.3.3 Government-backed digitalization in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Shortage of skilled pathologists and technicians
    • 5.2.4.2 Algorithm validation and trust in AI-based diagnostics
    • 5.2.4.3 Data security and privacy concerns
• 5.3 INDUSTRY TRENDS
  • 5.3.1 AI-POWERED DIAGNOSTICS GO MAINSTREAM
  • 5.3.2 CLOUD-BASED PLATFORMS AND REMOTE ACCESS BECOME CRITICAL ENABLERS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 CLOUD STORAGE & ARCHIVING
  • 5.4.2 WHOLE SLIDE IMAGING (WSI) SCANNERS
  • 5.4.3 IMAGE MANAGEMENT SYSTEMS
  • 5.4.4 ADJACENT TECHNOLOGIES
    • 5.4.4.1 Genomic sequencing
    • 5.4.4.2 Artificial Intelligence and Machine Learning
  • 5.4.5 COMPLEMENTARY TECHNOLOGIES
    • 5.4.5.1 LIS & PACS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY REGION
  • 5.5.2 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 PORTER'S FIVE FORCES ANALYSIS
  • 5.8.1 THREAT OF NEW ENTRANTS
  • 5.8.2 THREAT OF SUBSTITUTES
  • 5.8.3 BARGAINING POWER OF SUPPLIERS
  • 5.8.4 BARGAINING POWER OF BUYERS
  • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.9 HS CODES
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.10.2 REGULATORY ANALYSIS
    • 5.10.2.1 North America
      • 5.10.2.1.1 US
      • 5.10.2.1.2 Canada
    • 5.10.2.2 Europe
    • 5.10.2.3 Asia Pacific
      • 5.10.2.3.1 Japan
      • 5.10.2.3.2 China
      • 5.10.2.3.3 India
• 5.11 PATENT ANALYSIS
  • 5.11.1 PATENT PUBLICATION TRENDS
  • 5.11.2 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR DIGITAL PATHOLOGY PATENTS
  • 5.11.3 MAJOR PATENTS
• 5.12 CASE STUDY ANALYSIS
• 5.13 KEY CONFERENCES & EVENTS, 2025-2026
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
  • 5.14.3 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.15 END-USER ANALYSIS
  • 5.15.1 UNMET NEEDS
  • 5.15.2 END-USER EXPECTATIONS
• 5.16 BUSINESS MODEL ANALYSIS
• 5.17 INVESTMENT & FUNDING SCENARIO
• 5.18 IMPACT OF AI ON DIGITAL PATHOLOGY MARKET
• 5.19 IMPACT OF US TARIFF ON DIGITAL PATHOLOGY MARKET
  • 5.19.1 INTRODUCTION
  • 5.19.2 KEY TARIFF RATES
• 5.20 PRICE IMPACT ANALYSIS
• 5.21 IMPACT ON COUNTRY/REGION
  • 5.21.1 US
  • 5.21.2 EUROPE
  • 5.21.3 ASIA PACIFIC
  • 5.21.4 IMPACT ON END-USE INDUSTRIES

6 DIGITAL PATHOLOGY MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 SCANNERS
  • 6.2.1 BRIGHTFIELD SCANNERS
    • 6.2.1.1 Cost-efficient features to boost demand
  • 6.2.2 FLUORESCENCE SCANNERS
    • 6.2.2.1 Ability to detect cellular structures and biomarkers to fuel uptake
  • 6.2.3 OTHER SCANNERS
• 6.3 SOFTWARE
  • 6.3.1 INTEGRATED SOFTWARE
    • 6.3.1.1 Single & effective suite for multiple applications to propel market
  • 6.3.2 STANDALONE SOFTWARE
    • 6.3.2.1 Information management software
      • 6.3.2.1.1 Management of image repositories to fuel uptake
    • 6.3.2.2 Image analysis software
      • 6.3.2.2.1 Ability to automate quantitative evaluation to support market growth
• 6.4 SOFTWARE, BY DEPLOYMENT MODEL
  • 6.4.1 CLOUD-BASED MODEL
    • 6.4.1.1 Facilitation of collaboration on a single platform to drive market
  • 6.4.2 ON-PREMISE MODEL
    • 6.4.2.1 High data security and integration with HCIT solutions to fuel uptake
  • 6.4.3 HYBRID MODEL
    • 6.4.3.1 Combined flexibility to support market growth
• 6.5 STORAGE SYSTEMS
  • 6.5.1 GROWING FOCUS ON STORAGE OF HIGH-RESOLUTION IMAGES TO DRIVE MARKET

7 DIGITAL PATHOLOGY MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 HUMAN PATHOLOGY
  • 7.2.1 INCREASING CANCER RESEARCH ACTIVITIES TO PROPEL MARKET
• 7.3 VETERINARY PATHOLOGY
  • 7.3.1 IMPROVEMENTS IN ANIMAL DISEASE DIAGNOSTICS TO SUPPORT MARKET GROWTH

8 DIGITAL PATHOLOGY MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 DRUG DISCOVERY
  • 8.2.1 INCREASING FOCUS ON LIFE SCIENCES R&D TO DRIVE MARKET
• 8.3 DISEASE DIAGNOSIS
  • 8.3.1 INTEGRATION OF AI & ML IN COMPLEX DIAGNOSTICS TO BOOST DEMAND
• 8.4 TRAINING & EDUCATION
  • 8.4.1 ABILITY TO PROVIDE REAL-TIME LEARNING EXPERIENCES TO SUPPORT MARKET GROWTH

9 DIGITAL PATHOLOGY MARKET, BY END USER

• 9.1 INTRODUCTION
• 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.2.1 INCREASING FOCUS ON DRUG TOXICOLOGY TESTING AND RISING NUMBER OF PRECLINICAL TRIALS TO PROPEL MARKET
• 9.3 HOSPITALS & REFERENCE LABORATORIES
  • 9.3.1 HIGH INCIDENCE OF INFECTIOUS DISEASES TO BOOST DEMAND
• 9.4 ACADEMIC & RESEARCH INSTITUTES
  • 9.4.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH
• 9.5 DIAGNOSTICS LABORATORIES
  • 9.5.1 INCREASING PUBLIC & PRIVATE FUNDING INVESTMENTS TO SUPPORT MARKET GROWTH
• 9.6 VETERINARY LABORATORIES
  • 9.6.1 TECHNOLOGICAL ADVANCEMENTS, PARTICULARLY IN WHOLE-SLIDE IMAGING SYSTEMS AND AI-POWERED IMAGE ANALYSIS SOFTWARE, SUPPORT MARKET GROWTH

10 DIGITAL PATHOLOGY MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 NORTH AMERICA: MACROECONOMIC OUTLOOK
  • 10.2.2 US
    • 10.2.2.1 Favorable reimbursements for diagnostics to drive market
  • 10.2.3 CANADA
    • 10.2.3.1 Growing awareness on early cancer detection & diagnosis to drive market
• 10.3 EUROPE
  • 10.3.1 EUROPE: MACROECONOMIC OUTLOOK
  • 10.3.2 GERMANY
    • 10.3.2.1 High healthcare expenditure and supportive research initiatives to drive market
  • 10.3.3 UK
    • 10.3.3.1 Government funding investments for pathology services to fuel market
  • 10.3.4 SWEDEN
    • 10.3.4.1 Increasing prevalence of chronic diseases to support market growth
  • 10.3.5 FRANCE
    • 10.3.5.1 Increasing government funding and favorable insurance system to drive adoption
  • 10.3.6 SPAIN
    • 10.3.6.1 Supportive collaborations among leading companies and hospitals to boost demand
  • 10.3.7 ITALY
    • 10.3.7.1 Integration of AI & ML to support market growth
  • 10.3.8 REST OF EUROPE
• 10.4 ASIA PACIFIC
  • 10.4.1 ASIA PACIFIC: MACROECONOMIC OUTLOOK
  • 10.4.2 CHINA
    • 10.4.2.1 Increasing establishment of hospitals and reference laboratories to drive market
  • 10.4.3 JAPAN
    • 10.4.3.1 Advanced healthcare infrastructure to support market growth
  • 10.4.4 INDIA
    • 10.4.4.1 Growth in pharmaceutical industry to propel market
  • 10.4.5 REST OF ASIA PACIFIC
• 10.5 LATIN AMERICA
  • 10.5.1 LATIN AMERICA: MACROECONOMIC OUTLOOK
  • 10.5.2 BRAZIL
    • 10.5.2.1 High adoption of POC testing to drive market
  • 10.5.3 MEXICO
    • 10.5.3.1 Growth in companion diagnostics to fuel uptake
  • 10.5.4 REST OF LATIN AMERICA
• 10.6 MIDDLE EAST & AFRICA
  • 10.6.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH
  • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.6.3 GCC COUNTRIES
  • 10.6.4 REST OF MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL PATHOLOGY MARKET
• 11.3 REVENUE ANALYSIS
• 11.4 MARKET SHARE ANALYSIS
• 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.5.1 STARS
  • 11.5.2 EMERGING LEADERS
  • 11.5.3 PERVASIVE PLAYERS
  • 11.5.4 PARTICIPANTS
  • 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 11.5.5.1 Company footprint
    • 11.5.5.2 Product footprint
    • 11.5.5.3 Application footprint
    • 11.5.5.4 End-user footprint
    • 11.5.5.5 Region footprint
• 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.6.1 PROGRESSIVE COMPANIES
  • 11.6.2 RESPONSIVE COMPANIES
  • 11.6.3 DYNAMIC COMPANIES
  • 11.6.4 STARTING BLOCKS
  • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
• 11.7 COMPANY VALUATION AND FINANCIAL METRICS
• 11.8 BRAND/SOFTWARE COMPARATIVE ANALYSIS
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS
  • 11.9.2 DEALS
  • 11.9.3 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY COMPANIES
  • 12.1.1 DANAHER CORPORATION
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Deals
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 HOFFMANN-LA ROCHE LTD.
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 Recent developments
      • 12.1.2.3.1 Product launches & approvals
      • 12.1.2.3.2 Deals
    • 12.1.2.4 MnM view
      • 12.1.2.4.1 Key strengths
      • 12.1.2.4.2 Strategic choices
      • 12.1.2.4.3 Weaknesses and competitive threats
  • 12.1.3 SECTRA AB
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Deals
      • 12.1.3.3.2 Other developments
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 HAMAMATSU PHOTONICS K.K.
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Product approvals
      • 12.1.4.3.2 Deals
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 KONINKLIJKE PHILIPS N.V.
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches & approvals
      • 12.1.5.3.2 Deals
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 AKOYA BIOSCIENCES, INC.
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 Recent developments
      • 12.1.6.3.1 Product launches & approvals
  • 12.1.7 FUJIFILM HOLDINGS CORPORATION
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Deals
  • 12.1.8 HOLOGIC, INC.
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 Recent developments
      • 12.1.8.3.1 Product approvals
  • 12.1.9 3DHISTECH LTD.
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Product launches & enhancements
      • 12.1.9.3.2 Other developments
  • 12.1.10 APOLLO ENTERPRISE IMAGING CORP.
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 Recent developments
      • 12.1.10.3.1 Product enhancements
      • 12.1.10.3.2 Deals
  • 12.1.11 XIFIN, INC.
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
    • 12.1.11.3 Recent developments
      • 12.1.11.3.1 Product launches
      • 12.1.11.3.2 Deals
  • 12.1.12 HURON DIGITAL PATHOLOGY
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
      • 12.1.12.2.1 Deals
  • 12.1.13 INDICA LABS
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 Recent developments
      • 12.1.13.3.1 Product launches & approvals
      • 12.1.13.3.2 Deals
  • 12.1.14 OPTRASCAN, INC.
    • 12.1.14.1 Business overview
    • 12.1.14.2 Products offered
    • 12.1.14.3 Recent developments
      • 12.1.14.3.1 Product launches & approvals
      • 12.1.14.3.2 Deals
  • 12.1.15 GLENCOE SOFTWARE, INC.
    • 12.1.15.1 Business overview
    • 12.1.15.2 Products offered
    • 12.1.15.3 Recent developments
      • 12.1.15.3.1 Product enhancements
  • 12.1.16 AIFORIA TECHNOLOGIES OY
    • 12.1.16.1 Business overview
    • 12.1.16.2 Products offered
    • 12.1.16.3 Recent developments
      • 12.1.16.3.1 Deals
  • 12.1.17 PAIGE AI, INC.
    • 12.1.17.1 Business overview
    • 12.1.17.2 Products offered
    • 12.1.17.3 Recent developments
      • 12.1.17.3.1 Product launches & enhancements
      • 12.1.17.3.2 Deals
  • 12.1.18 PROSCIA, INC.
    • 12.1.18.1 Business overview
    • 12.1.18.2 Products offered
    • 12.1.18.3 Recent developments
      • 12.1.18.3.1 Product enhancements & approvals
      • 12.1.18.3.2 Deals
• 12.2 OTHER PLAYERS
  • 12.2.1 QUEST DIAGNOSTICS
  • 12.2.2 KONFOONG BIOTECH INTERNATIONAL CO., LTD.
  • 12.2.3 MIKROSCAN TECHNOLOGIES, INC.
  • 12.2.4 MOTIC DIGITAL PATHOLOGY
  • 12.2.5 KANTERON SYSTEMS
  • 12.2.6 MORPHLE LABS INC.
  • 12.2.7 EW HEALTHCARE PARTNERS

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS